[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
September 21, 2011

Evolving Research and Stakeholder Perspectives on Pharmacogenomics

Author Affiliations

Author Affiliations: University of Maryland School of Medicine, Department of Medicine, Baltimore (Dr Beitelshees); and University of Washington, Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, Seattle (Dr Veenstra).

JAMA. 2011;306(11):1252-1253. doi:10.1001/jama.2011.1343

The past decade has been a time of important change in pharmacogenomics. There is an increasingly clear understanding of the relationship between genetic variation and drug response, low-cost testing technologies are becoming available, and pharmacogenomics is playing an increasing role in drug development. Key stakeholders in the US health care system are responding to these changes in various fashions. In this Commentary, we provide a brief overview of these developments and assess the implications for clinical practice.

First Page Preview View Large
First page PDF preview
First page PDF preview
×